Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Financing Activities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash from Financing Activities for 16 consecutive years, with -$403.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to -$403.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $425.4 million, a N/A change, with the full-year FY2025 number at $524.5 million, down 43.64% from a year prior.
  • Cash from Financing Activities was -$403.8 million for Q4 2025 at Cytokinetics, down from $4.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $821.0 million in Q2 2024 to a low of -$403.8 million in Q4 2025.
  • A 5-year average of $93.3 million and a median of $19.5 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 32590.91% in 2021, then soared 14895.63% in 2024.
  • Cytokinetics' Cash from Financing Activities stood at $19.5 million in 2021, then skyrocketed by 53.21% to $29.9 million in 2022, then skyrocketed by 464.83% to $168.8 million in 2023, then tumbled by 97.97% to $3.4 million in 2024, then plummeted by 11888.88% to -$403.8 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Cash from Financing Activities are -$403.8 million (Q4 2025), $4.8 million (Q1 2025), and $3.4 million (Q3 2024).